WO2020212999A1 - Extraction of cannabinoids, flavonoids and terpenes from cannabis - Google Patents

Extraction of cannabinoids, flavonoids and terpenes from cannabis Download PDF

Info

Publication number
WO2020212999A1
WO2020212999A1 PCT/IN2019/050520 IN2019050520W WO2020212999A1 WO 2020212999 A1 WO2020212999 A1 WO 2020212999A1 IN 2019050520 W IN2019050520 W IN 2019050520W WO 2020212999 A1 WO2020212999 A1 WO 2020212999A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
cannabis
flavonoids
extraction
terpenes
Prior art date
Application number
PCT/IN2019/050520
Other languages
French (fr)
Inventor
Gordon COOPER EAMES HELLEGER
Original Assignee
Asheesh Concentrates
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2021012385A priority Critical patent/MX2021012385A/en
Application filed by Asheesh Concentrates filed Critical Asheesh Concentrates
Priority to AU2019441432A priority patent/AU2019441432A1/en
Priority to KR1020217035397A priority patent/KR20220003530A/en
Priority to BR112021020720A priority patent/BR112021020720A2/en
Priority to US17/603,650 priority patent/US20220233619A1/en
Priority to CN201980097337.XA priority patent/CN114302720A/en
Priority to CA3137282A priority patent/CA3137282A1/en
Priority to EP19925156.2A priority patent/EP3955915A4/en
Priority to MA54666A priority patent/MA54666B2/en
Priority to JP2021561603A priority patent/JP2022529931A/en
Publication of WO2020212999A1 publication Critical patent/WO2020212999A1/en
Priority to ZA2021/07871A priority patent/ZA202107871B/en
Priority to CONC2021/0014407A priority patent/CO2021014407A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0203—Solvent extraction of solids with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0269—Solid material in other moving receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0288—Applications, solvents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/14—Extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • This invention generally relates to a method of extracting natural products from a plant or plant material. More particularly, the invention relates to a method of extracting cannabinoids, flavonoids and terpenes from a Cannabis genus of plant.
  • Cannabinoid-containing plant extracts are in high demand due to the medicinal value and other applications and may be obtained by various means of extraction of cannabis plant material. Such means include but are not limited to: supercritical or subcritical extraction with carbon dioxide (C02), extraction with hot gas and extraction with solvents. These methods, which are known by those skilled in the art, are deficient for many reasons.
  • C02 supercritical or subcritical extraction with carbon dioxide
  • the extract is further purified by refinement necessary to remove components of the concentrate which are not desirable for primary medical applications, such as lipids, waxes and residual moisture, all of which dilute the active compounds, such as cannabinoids, terpenoids and flavonoids, and compromise the concentrate by hastening its degradation.
  • the terpene and flavonoid components of cannabis have medical value, and are used in many medical preparations, but their concentration is low in typical C02 extraction methodologies for multiple reasons. This is largely due to the relatively low volatility points of most terpenes and flavonoids commonly found in cannabis, and their volatilization makes their concentration impractical under typical C02 parameters and refinement processes.
  • the refinement methodologies typically applied to C02 concentrates further disturb and dilute the presence of terpene and flavonoid compounds in resultant, refined cannabis concentrates. This is due to the exposure of the concentrate during refinement, to temperatures in excess of the volatility points of the aromatic compounds, thus, degradation takes place if the compounds are re-captured, or they are completely lost and no longer components of the refined concentrate. These conditions are necessary when using typical methods which require the addition and subsequent removal of a secondary solvent. To achieve solvent volatilization for removal from the concentrate, the volatility points of the terpenes and flavonoids are exceeded and thus, at best, degradation takes place if the compounds are re-captured, or they are completely lost through the process of purging the solvent and are no longer components of the refined concentrate. If the solvent is not volatilized and purged, the quality of the concentrate is greatly diminished and potentially hazardous, because of the unavoidable levels of residual solvent retained within the concentrate itself.
  • a cheaper and safer extraction of cannabinoid from a Cannabis genus of plant is desired.
  • the process should ideally produces a high overall yield of extract comprising cannabinoid, along with flavonoids and terpenes. It is further desired that the extract contains substantially no waxes, resins or other undesirable compounds.
  • a methodology of concentration which maintains as much of the plant’s complete spectrum of active compounds as possible, has no residual solvent and is of high purity, is needed to be developed.
  • the invention provides a solvent-free process for preparing an extract from cannabis comprising
  • the invention provides a cannabis extract comprising cannabinoid in a range of 30-75%, terpenes in a range of 5-35% and flavonoids.
  • the present invention is directed towards a process for preparing an extract from cannabis and the extract prepared therefrom, wherein the extract is a high-purity refined cannabis concentrate which is rich in cannabinoids, flavonoids, terpenes, and provides a broad-spectrum of the original plant-based compounds. This process ensures the most minimal degradation of volatile plant-based compounds.
  • the present invention provides a process for preparing an extract from cannabis comprising >- an extraction step of treating the cannabis with carbon dioxide at a temperature of between 0 °C to 15 °C and a pressure between 1250 psi and 1600 psi to obtain an extract;
  • extraction step is followed by a decarboxylation step preferably between 115°C to 14o°C and then centrifugation at 16°C to 27°C.
  • decarboxylation step preferably between 115°C to 14o°C and then centrifugation at 16°C to 27°C.
  • the centrifuging is conducted in a refrigerated centrifuge resulting in a mechanical separation of the components of the concentrate. Lipids, waxes and moisture will separate from the desired concentrate material without de-naturing the aromatic profile, as long as the temperatures are strictly controlled.
  • the centrifuging typically takes place over a series of cycles through the centrifuge with RPM’s between 5,000 and 12,000 and durations between 30 minutes and 6 hours.
  • the temperature range of between 20°C and 40°C ideally utilizes increasing temperature and pressure in subsequent cycles, once the more easily separated components are removed to minimize their exposure to higher temperatures.
  • the invention also relates to a cannabis extract comprising cannabinoid in a range of 30-75%, terpenes 5-35% and flavonoids.
  • the cannabis extract is obtained in an yield by mass of 6 - 20%.
  • the extract may be used in a wide range of applications and can be added as a concentrate in pharmaceuticals, foods, herbal preparations, supplements.
  • the process as a whole is a set of processes whose significance lies in their combination and specificity, resulting in a refined cannabis extract.
  • the extract is obtained through a single stage of extraction, as opposed to conventional practices including multiple- stage process, and without the use of a secondary solvent based winterization process.
  • the extract provides a high degree of medically significant plant extract in a stable form.
  • Cannabis plant material was cultivated under the medical cannabis laws of the State of
  • the plant material was subjected to pre -extraction processes and prepared to specifications, which included the removal of the non-flower plant components, appropriate moisture level, appropriate process temperature control, etc. Subsequently, the plant material, preferably the flowering part, was ground and loaded into a C02 extraction machine. The machine was operated within a specific set of parameters which allowed for concentration to take place, and there was an accumulation of “crude” concentrate which was removed from the collection chamber. This material was then loaded into centrifuge tubes, and passed through an initial process of centrifugation, at the beginning of the centrifuge protocol designated. From here, there was a manual separation process to remove the purified oils from the lipids, waxes and water contaminants. Then, further steps of the centrifugation protocol were utilized to more thoroughly and completely refine the concentrate until the process was complete. The resultant concentrate was utilized as per product development goals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a process for preparing an extract from cannabis comprising an extraction step of treating the cannabis with carbon dioxide at a temperature of between 0 °C to 15 °C and a pressure between 1250 psi and 1600 psi to obtain an extract; and centrifuging the extract between 20°C to 40°C.

Description

TITLE OF THE INVENTION
Extraction of cannabinoids, flavonoids and terpenes from cannabis
FIELD OF THE INVENTION
This invention generally relates to a method of extracting natural products from a plant or plant material. More particularly, the invention relates to a method of extracting cannabinoids, flavonoids and terpenes from a Cannabis genus of plant.
BACKGROUND OF THE INVENTION
Cannabinoid-containing plant extracts are in high demand due to the medicinal value and other applications and may be obtained by various means of extraction of cannabis plant material. Such means include but are not limited to: supercritical or subcritical extraction with carbon dioxide (C02), extraction with hot gas and extraction with solvents. These methods, which are known by those skilled in the art, are deficient for many reasons.
One problem with the supercritical carbon dioxide extraction is that the cost of the equipment makes it cost-prohibitive. It is also done under high pressure (2000-5000 psig, or pounds per square inch gage), which is generally detrimental to the quality and yield of the final product extract. The method also produces low purity extract (30-70% pure THC, 3-10% by weight of the plant) (Murty et al, US Publication No. 2003/0050334) and there is also a significant amount of water that binds to the THC. Another drawback to supercritical C02 extraction is that it is performed in small batches. Each batch can take up to eight hours to complete. Also, and similar to non-polar solvent extraction methods, the extract is further purified by refinement necessary to remove components of the concentrate which are not desirable for primary medical applications, such as lipids, waxes and residual moisture, all of which dilute the active compounds, such as cannabinoids, terpenoids and flavonoids, and compromise the concentrate by hastening its degradation.
The terpene and flavonoid components of cannabis have medical value, and are used in many medical preparations, but their concentration is low in typical C02 extraction methodologies for multiple reasons. This is largely due to the relatively low volatility points of most terpenes and flavonoids commonly found in cannabis, and their volatilization makes their concentration impractical under typical C02 parameters and refinement processes.
The refinement methodologies typically applied to C02 concentrates further disturb and dilute the presence of terpene and flavonoid compounds in resultant, refined cannabis concentrates. This is due to the exposure of the concentrate during refinement, to temperatures in excess of the volatility points of the aromatic compounds, thus, degradation takes place if the compounds are re-captured, or they are completely lost and no longer components of the refined concentrate. These conditions are necessary when using typical methods which require the addition and subsequent removal of a secondary solvent. To achieve solvent volatilization for removal from the concentrate, the volatility points of the terpenes and flavonoids are exceeded and thus, at best, degradation takes place if the compounds are re-captured, or they are completely lost through the process of purging the solvent and are no longer components of the refined concentrate. If the solvent is not volatilized and purged, the quality of the concentrate is greatly diminished and potentially hazardous, because of the unavoidable levels of residual solvent retained within the concentrate itself.
A cheaper and safer extraction of cannabinoid from a Cannabis genus of plant is desired. The process should ideally produces a high overall yield of extract comprising cannabinoid, along with flavonoids and terpenes. It is further desired that the extract contains substantially no waxes, resins or other undesirable compounds. Thus, a methodology of concentration, which maintains as much of the plant’s complete spectrum of active compounds as possible, has no residual solvent and is of high purity, is needed to be developed. SUMMARY OF THE INVENTION
In one aspect, the invention provides a solvent-free process for preparing an extract from cannabis comprising
>- an extraction step of treating the cannabis with carbon dioxide at a temperature of between 0 °C to 15 °C and a pressure between 1250 psi and 1600 psi to obtain an extract; and
>- centrifuging the extract between 20°C to 40°C.
In another aspect, the invention provides a cannabis extract comprising cannabinoid in a range of 30-75%, terpenes in a range of 5-35% and flavonoids.
DESCRIPTION OF THE INVENTION
The present invention is directed towards a process for preparing an extract from cannabis and the extract prepared therefrom, wherein the extract is a high-purity refined cannabis concentrate which is rich in cannabinoids, flavonoids, terpenes, and provides a broad-spectrum of the original plant-based compounds. This process ensures the most minimal degradation of volatile plant-based compounds.
In one aspect, the present invention provides a process for preparing an extract from cannabis comprising >- an extraction step of treating the cannabis with carbon dioxide at a temperature of between 0 °C to 15 °C and a pressure between 1250 psi and 1600 psi to obtain an extract; and
>- centrifuging the extract between 20°C to 40°C.
In this regard, extraction step is followed by a decarboxylation step preferably between 115°C to 14o°C and then centrifugation at 16°C to 27°C. These parameters allow for a comprehensive spectrum of the cannabinoid, terpenoid and flavonoid profiles of the plant matter to be concentrated effectively without the de-naturing that takes place at higher temperatures and pressures. Also, the extraction process that occurs under these parameters leaves much of the waxes and lipids behind in the plant matter and does not include them in the resultant concentrate, thus facilitating future refinement.
In an embodiment of the invention, the centrifuging is conducted in a refrigerated centrifuge resulting in a mechanical separation of the components of the concentrate. Lipids, waxes and moisture will separate from the desired concentrate material without de-naturing the aromatic profile, as long as the temperatures are strictly controlled. In this regard, the centrifuging typically takes place over a series of cycles through the centrifuge with RPM’s between 5,000 and 12,000 and durations between 30 minutes and 6 hours. The temperature range of between 20°C and 40°C, ideally utilizes increasing temperature and pressure in subsequent cycles, once the more easily separated components are removed to minimize their exposure to higher temperatures.
By carefully controlling the temperature and pressure below the super-critical temperature and pressure, it has been possible to separate out specific fractions rich in cannabinoids along with the terpenes and flavonoids which can be separated relatively easily to obtain an extract which contains the desirable components in an acceptable form.
Furthermore, very good batch-to-batch reproducibility can be obtained between batches and unwanted constituents, such as waxes, resins or other undesirable compounds which may be present to varying extents in the raw material, can be left behind in the exhausted material.
In another aspect, the invention also relates to a cannabis extract comprising cannabinoid in a range of 30-75%, terpenes 5-35% and flavonoids.
In an embodiment, the cannabis extract is obtained in an yield by mass of 6 - 20%.
In yet another aspect, the extract may be used in a wide range of applications and can be added as a concentrate in pharmaceuticals, foods, herbal preparations, supplements.
Advantageously, the process as a whole is a set of processes whose significance lies in their combination and specificity, resulting in a refined cannabis extract. The extract is obtained through a single stage of extraction, as opposed to conventional practices including multiple- stage process, and without the use of a secondary solvent based winterization process. Thus, the extract provides a high degree of medically significant plant extract in a stable form.
EXAMPLES
The following experimental examples are illustrative of the invention but not limitative of the scope thereof:
Cannabis plant material was cultivated under the medical cannabis laws of the State of
California. The plant material was subjected to pre -extraction processes and prepared to specifications, which included the removal of the non-flower plant components, appropriate moisture level, appropriate process temperature control, etc. Subsequently, the plant material, preferably the flowering part, was ground and loaded into a C02 extraction machine. The machine was operated within a specific set of parameters which allowed for concentration to take place, and there was an accumulation of “crude” concentrate which was removed from the collection chamber. This material was then loaded into centrifuge tubes, and passed through an initial process of centrifugation, at the beginning of the centrifuge protocol designated. From here, there was a manual separation process to remove the purified oils from the lipids, waxes and water contaminants. Then, further steps of the centrifugation protocol were utilized to more thoroughly and completely refine the concentrate until the process was complete. The resultant concentrate was utilized as per product development goals.
The foregoing description of the invention has been set merely to illustrate the invention and is not intended to be limiting. Since the modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to the person skilled in the art, the invention should be construed to include everything within the scope of the disclosure.

Claims

Claims:
1. A process for preparing an extract from cannabis comprising
>- an extraction step of treating the cannabis with carbon dioxide at a temperature of between 0 °C to 15 °C and a pressure between 1250 psi and 1600 psi to obtain an extract; and >- centrifuging the extract between 20°C to 40°C.
2. The solvent-free process as claimed in claim 1, wherein the extraction step is followed by decarboxylation step before the centrifugation.
3. The solvent-free process as claimed in claim 1, wherein the centrifuging is carried out multiple times at an RPM of between 5000 - 12000.
4. The solvent-free process as claimed in claim 1, wherein the centrifuging is followed by a manual separation.
5. The solvent-free process as claimed in claim 1, wherein the extract comprises cannabinoids, terpenes and flavonoids.
6. A cannabis extract comprising cannabinoid in a range of 30-75%, terpenes 5-35% and flavonoids.
7. The cannabis extract as claimed in claim 6, wherein the extract is used as concentrate in medicament, pharmaceutical product, cosmetic product and food additive, herbal preparations and supplements.
PCT/IN2019/050520 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids and terpenes from cannabis WO2020212999A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201980097337.XA CN114302720A (en) 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids and terpenes from cannabis sativa
AU2019441432A AU2019441432A1 (en) 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids and terpenes from cannabis
KR1020217035397A KR20220003530A (en) 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids and terpenes from hemp
BR112021020720A BR112021020720A2 (en) 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids and terpenes from cannabis
US17/603,650 US20220233619A1 (en) 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids and terpenes from cannabis
MX2021012385A MX2021012385A (en) 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids and terpenes from cannabis.
CA3137282A CA3137282A1 (en) 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids and terpenes from cannabis
JP2021561603A JP2022529931A (en) 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids, and terpenes from cannabis
MA54666A MA54666B2 (en) 2019-04-17 2019-07-12 EXTRACTION OF CANNABINOIDS, FLAVONOIDS AND TERPENES FROM CANNABIS
EP19925156.2A EP3955915A4 (en) 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids and terpenes from cannabis
ZA2021/07871A ZA202107871B (en) 2019-04-17 2021-10-15 Extraction of cannabinoids, flavonoids and terpenes from cannabis
CONC2021/0014407A CO2021014407A2 (en) 2019-04-17 2021-10-27 Cannabinoid, flavonoid and terpene extraction from cannabis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921015397 2019-04-17
IN201921015397 2019-04-17

Publications (1)

Publication Number Publication Date
WO2020212999A1 true WO2020212999A1 (en) 2020-10-22

Family

ID=72838096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2019/050520 WO2020212999A1 (en) 2019-04-17 2019-07-12 Extraction of cannabinoids, flavonoids and terpenes from cannabis

Country Status (13)

Country Link
US (1) US20220233619A1 (en)
EP (1) EP3955915A4 (en)
JP (1) JP2022529931A (en)
KR (1) KR20220003530A (en)
CN (1) CN114302720A (en)
AU (1) AU2019441432A1 (en)
BR (1) BR112021020720A2 (en)
CA (1) CA3137282A1 (en)
CO (1) CO2021014407A2 (en)
MA (1) MA54666B2 (en)
MX (1) MX2021012385A (en)
WO (1) WO2020212999A1 (en)
ZA (1) ZA202107871B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016277A2 (en) * 2002-08-14 2004-02-26 Gw Pharma Limited Extraction of pharmaceutically active cannabinoids from plant materials
US20180344785A1 (en) * 2016-04-11 2018-12-06 Bradley Lee Robertson Methods for Extraction and Isolation of Isoprenoid and Terpene Compounds from Biological Extracts

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (en) * 2000-10-17 2002-06-13 Adam Mueller Process for the production of an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material and cannabis extracts
MXPA05001567A (en) * 2002-08-14 2005-04-25 Gw Pharma Ltd Cannabinoid liquid formulations for mucosal amdinistration.
US7344736B2 (en) * 2002-08-14 2008-03-18 Gw Pharma Limited Extraction of pharmaceutically active components from plant materials
US20170333503A1 (en) * 2015-06-09 2017-11-23 Total Health Care I Process for extraction, separation and purification of cannabinoids, flavonoids and terpenes from cannabis
US10625175B2 (en) * 2016-04-06 2020-04-21 Kiinja Corporation Extractor for high pressure extraction of a matrix
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016277A2 (en) * 2002-08-14 2004-02-26 Gw Pharma Limited Extraction of pharmaceutically active cannabinoids from plant materials
US20180344785A1 (en) * 2016-04-11 2018-12-06 Bradley Lee Robertson Methods for Extraction and Isolation of Isoprenoid and Terpene Compounds from Biological Extracts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3955915A4 *

Also Published As

Publication number Publication date
US20220233619A1 (en) 2022-07-28
KR20220003530A (en) 2022-01-10
CA3137282A1 (en) 2020-10-22
CN114302720A (en) 2022-04-08
MA54666B2 (en) 2023-10-31
BR112021020720A2 (en) 2021-12-14
EP3955915A1 (en) 2022-02-23
MA54666A1 (en) 2022-09-30
JP2022529931A (en) 2022-06-27
AU2019441432A1 (en) 2021-11-11
EP3955915A4 (en) 2023-01-25
ZA202107871B (en) 2022-09-28
CO2021014407A2 (en) 2021-11-19
MX2021012385A (en) 2022-01-18

Similar Documents

Publication Publication Date Title
EP2844243B1 (en) Method for preparing a cannabis plant isolate comprising delta-9-tetrahydrocannabinol
Junior et al. Supercritical fluid extraction and stabilization of phenolic compounds from natural sources–review (supercritical extraction and stabilization of phenolic compounds)
AU722774B2 (en) A process for the extraction of lycopene and extracts containing it
Solana et al. Extraction of bioactive enriched fractions from Eruca sativa leaves by supercritical CO2 technology using different co-solvents
JP2019524655A (en) Decarbonized cannabis resin, its use, and process for producing it
US20180280459A1 (en) Methods for the production of different cannabis product compositions
US20180344785A1 (en) Methods for Extraction and Isolation of Isoprenoid and Terpene Compounds from Biological Extracts
JP2009525863A (en) Near critical fluid extraction method
Srinivas et al. Supercritical carbon dioxide and subcritical water: Complementary agents in the processing of functional foods
US10934238B2 (en) Organic solubilisation and/or extraction solvent, extraction method using said solvent, and extracts obtained by said method
JPH0617050A (en) Production of antioxidant derived from natural plant
JP2009504816A (en) Method for obtaining natural oil from plant components
EP3955915A1 (en) Extraction of cannabinoids, flavonoids and terpenes from cannabis
KR101722829B1 (en) Method of Removing Residual Agricultural Chemicals from Plant
RU2796495C2 (en) Extraction of cannabinoids, flavonoids and terpenes from cannabis
JPH08509523A (en) Process for producing ultra-high purity egg oil and its use
EP1401459B1 (en) Method of providing an essential oil extract of capsicum, and the extract
US20220211789A1 (en) Extraction of cannabinoids from biomass
WO2007062206A2 (en) Chocolate formulations with functional properties
JPH03115225A (en) Removal of blight from carrot root
FR2771408A1 (en) Use of hydrofluoro ethers as solvents for organic molecules
RU2739603C1 (en) Method for extracting essential oils from vegetable raw materials
US10113136B2 (en) Fractionation of frankincense resin using supercritical carbon dioxide
JP2001106636A (en) Production of plant extract
NZ577016A (en) Process for selective extraction and separation of organic materials by means of high pressure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19925156

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021561603

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3137282

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021020720

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019441432

Country of ref document: AU

Date of ref document: 20190712

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019925156

Country of ref document: EP

Effective date: 20211117

ENP Entry into the national phase

Ref document number: 112021020720

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211015